Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P 3 receptor: Investigation based on a new S1P3 receptor antagonist

Molecular Pharmacology

Volumn 77, Issue 4, 2010, Pages 704-713

  Murakami, Akira ^a   Takasugi, Hiroshi ^a   Ohnuma, Shinya ^a   Koide, Yuuki ^a   Sakurai, Atsuko ^c   Takeda, Satoshi ^b   Hasegawa, Takeshi ^a   Sasamori, Jun ^a   Konno, Takashi ^a   Hayashi, Kenji ^a   Watanabe, Yoshiaki ^a   Mori, Koji ^a   Sato, Yoshimichi ^a   Takahashi, Atsuo ^a   Mochizuki, Naoki ^c   Takakura, Nobuyuki ^d  

^a TOA EIYO LTD   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 CHLOROPHENYLHYDRAZONO) 1 (4 CHLOROPHENYLAMINO) 3,3 DIMETHYL 2 BUTANONE; 2 AMINO 2 (3 OCTYLPHENYLCARBAMOYL)ETHYL PHOSPHATE; 2 BUTANONE; 4 (2,6 DICHLORO 4 PYRIDINYL) 1 (1,3 DIMETHYL 4 ISOPROPYL 1H PYRAZOLO[3,4 B]PYRIDIN 6 YL)SEMICARBAZIDE; CALCIUM; RHO FACTOR; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 3; TY 52156; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; CALCIUM CELL LEVEL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; HEART CONTRACTION; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CALCIUM; CEREBRAL ARTERIES; CHO CELLS; CORONARY CIRCULATION; CRICETINAE; CRICETULUS; DOGS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEART RATE; HYDRAZONES; LYSOPHOSPHOLIPIDS; MALE; PHOSPHORYLATION; PROPYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LYSOSPHINGOLIPID; RHO-ASSOCIATED KINASES; SPHINGOSINE; VASOCONSTRICTION;

EID: 77950231687     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.061481     Document Type: Article

References (39)

1. Arikawa K, Takuwa N, Yamaguchi H, Sugimoto N, Kitayama J, Nagawa H, Takehara K, and Takuwa Y (2003) Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J Biol Chem 278:32841-32851.
2. Coussin F, Scott RH, Wise A, and Nixon GF (2002) Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res 91:151-157.
3. Dantas AP, Igarashi J, and Michel T (2003) Sphingosine 1-phosphate and control of vascular tone. Am J Physiol Heart Circ Physiol 284:H2045-2052.
4. Davignon J and Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109:III27-III32.
5. Davis MD, Clemens JJ, Macdonald TL, and Lynch KR (2005) Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem 280:9833-9841.
6. Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J, et al. (2004) Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 309:758-768.
7. Gergely P, Wallström E, Nuesslein-Hildesheim B, Bruns C, Zécri F, Cooke N, Traebert M, Tuntland T, Rosenberg M and Saltzman M (2009) Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans. Multiple Sclerosis 15 (9 Suppl):S235-S236.
8. Heldin CH and Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316.
9. Himmel HM, Meyer Zu Heringdorf D, Graf E, Dobrev D, Kortner A, Schüler S, Jakobs KH, and Ravens U (2000) Evidence for Edg-3 receptor-mediated activation of I(K.ACh) by sphingosine-1-phosphate in human atrial cardiomyocytes. Mol Pharmacol 58:449-454.
10. Huwiler A and Pfeilschifter J (2008) New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 75:1893-1900.
11. Igarashi J and Michel T (2000) Agonist-modulated targeting of the EDG-1 receptor to plasmalemmal caveolae. eNOS activation by sphingosine 1-phosphate and the role of caveolin-1 in sphingolipid signal transduction. J Biol Chem 275:32363-32370.
12. Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, Kingsbury MA, Yang AH, Zhang G, Brown JH, and Chun J (2002) Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. J Biol Chem 277:25152-25159.
13. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124-1140.
14. Kawano H and Ogawa H (2004) Endothelial dysfunction and coronary artery spasm. Curr Drug Targets Cardiovasc Haematol Disord 4:23-33.
15. Koide Y, Uemoto K, Hasegawa T, Sada T, Murakami A, Takasugi H, Sakurai A, Mochizuki N, Takahashi A, and Nishida A (2007) Pharmacophore-based design of sphingosine 1-phosphate-3 receptor antagonists that include a 3,4-dialkoxybenzophenone scaffold. J Med Chem 50:442-454.
16. Koyrakh L, Roman MI, Brinkmann V, and Wickman K (2005) The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 5:529-536.
17. Kugiyama K, Yasue H, Okumura K, Ogawa H, Fujimoto K, Nakao K, Yoshimura M, Motoyama T, Inobe Y, and Kawano H (1996) Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 94:266-271.
18. Levkau B, Hermann S, Theilmeier G, van der Giet M, Chun J, Schober O, and Schä fers M (2004) High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation 110:3355-3359.
19. Lim HS, Oh YS, Suh PG, and Chung SK (2003) Syntheses of sphingosine-1-phosphate stereoisomers and analogues and their interaction with EDG receptors. Bioorg Med Chem Lett 13:237-240.
20. Mazurais D, Robert P, Gout B, Berrebi-Bertrand I, Laville MP, and Calmels T (2002) Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 50:661-670.
21. 3H] A-369508 ([2-[4-(2-cyanophenyl) -1-piperazinyl]-N-(3-methylphenyl) acetamide]: an agonist radioligand selective for the dopamine D4 receptor. Eur J Pharmacol 497:147-154.
22. Nofer JR, van der Giet M, Tölle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Gödecke A, Ishii I, Kleuser B, et al. (2004) HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113:569-581.
23. Ohmori T, Yatomi Y, Osada M, Kazama F, Takafuta T, Ikeda H, and Ozaki Y (2003) Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res 58:170-177.
24. Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J, Kimura T, Tobo M, Yamazaki Y, Watanabe T, et al. (2003) Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 64:994-1005.
25. Pomposiello S, Yang XP, Liu YH, Surakanti M, Rhaleb NE, Sevilla M, and Carretero OA (1997) Autacoids mediate coronary vasoconstriction induced by nitric oxide synthesis inhibition. J Cardiovasc Pharmacol 30:599-606.
26. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, and Brown S (2009) Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 78:743-768.
27. Ryu Y, Takuwa N, Sugimoto N, Sakurada S, Usui S, Okamoto H, Matsui O, and Takuwa Y (2002) Sphingosine-1-phosphate, a platelet-derived lysophospholipid mediator, negatively regulates cellular Rac activity and cell migration in vascular smooth muscle cells. Circ Res 90:325-332.
28. Salomone S, Potts EM, Tyndall S, Ip PC, Chun J, Brinkmann V, and Waeber C (2008) Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools. Br J Pharmacol 153:140-147.
29. Salomone S, Yoshimura S, Reuter U, Foley M, Thomas SS, Moskowitz MA, and Waeber C (2003) S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur J Pharmacol 469:125-134.
30. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N, et al. (2004) Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279:13839-13848.
31. Sensken SC, Stäubert C, Keul P, Levkau B, Schöneberg T, and Gräler MH (2008) Selective activation of G alpha i mediated signalling of S1P3 by FTY720-phosphate. Cell Signal 20:1125-1133.
32. Siess W (2002) Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta 1582:204-215.
33. Sugimoto N, Takuwa N, Okamoto H, Sakurada S, and Takuwa Y (2003) Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol 23:1534-1545.
34. Sugiyama A, Yatomi Y, Ozaki Y, and Hashimoto K (2000) Sphingosine 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart. Cardiovasc Res 46:119-125.
35. Takuwa Y, Okamoto Y, Yoshioka K, and Takuwa N (2008) Sphingosine-1- phosphate signaling and biological activities in the cardiovascular system. Biochim Biophys Acta 1781:483-488.
36. Tosaka M, Okajima F, Hashiba Y, Saito N, Nagano T, Watanabe T, Kimura T, and Sasaki T (2001) Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm. Stroke 32:2913-2919.
37. Watterson KR, Ratz PH, and Spiegel S (2005) The role of sphingosine-1-phosphate in smooth muscle contraction. Cell Signal 17:289-298.
38. Yatomi Y (2006) Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. Curr Pharm Des 12:575-587.
39. Zemann B, Kinzel B, Müller M, Reuschel R, Mechtcheriakova D, Urtz N, Bornancin F, Baumruker T, and Billich A (2006) Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 107:1454-1458.